The maker of the anti-depressant Paxil agreed to pay $14 million to state drug-purchasing programs to settle allegations that it blocked generic versions of the drug from being made. The states had alleged that GlaxoSmithKline used frivolous patent infringement lawsuits against generic drug makers, triggering automatic extensions of the patent for Paxil. Critics call the patent extension "evergreening" but drug makers contend that it's a legitimate protection of the fruits of costly research.
March 29, 2006 at 12:00 AM
1 minute read
The original version of this story was published on Law.Com
The maker of the anti-depressant Paxil agreed to pay $14 million to state drug-purchasing programs to settle allegations that it blocked generic versions of the drug from being made, causing the states to pay higher prices.
A spokeswoman for GlaxoSmithKline said the company denied any wrongdoing and was not admitting liability in making the settlement, which mostly affects Medicaid programs.
Presented by BigVoodoo
The Legal Intelligencer honors lawyers leaving a mark on the legal community in Pennsylvania and Delaware.
Consulting Magazine recognizes leaders in technology across three categories Leadership, Client Service and Innovation.
Celebrate outstanding achievement in law firms, chambers, in-house legal departments and alternative business structures.
Truly exceptional Bergen County New Jersey Law Firm is growing and seeks strong plaintiff's personal injury Attorney with 5-7 years plaintif...
Epstein Becker & Green is seeking an associate to joins its Commercial Litigation practice in our Columbus or Cincinnati offices. Ca...
Job Opportunity: Location: Prestigious Florida Law Firm seeks to hire a Business attorney with at least 5 years of experience for their Ft. ...
MELICK & PORTER, LLP PROMOTES CONNECTICUT PARTNERS HOLLY ROGERS, STEVEN BANKS, and ALEXANDER AHRENS
